{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:51:21Z","timestamp":1790369481459,"version":"4.1.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,18]]},"abstract":"<jats:p>The prevalence of Obesity is increasing globally, including in T\u00fcrkiye, and affects all age groups, including the elderly. Previous clinical trials have shown the efficacy and safety of liraglutide in reducing the body weight of older adults. This study aimed to evaluate the effectiveness of liraglutide on weight loss and to identify any adverse effects in elderly individuals with obesity. This retrospective cohort study included patients aged\u2005\u2265\u200560 years with a body-mass index (BMI)\u2005\u2265\u200527 or greater and other comorbidities, as well as those with an initial BMI\u2005\u2265\u200530. All patients referred from a private tertiary clinic were prescribed liraglutide for obesity treatment. Data were collected from September 2023 to September 2024, with metabolic and anthropometric parameters recorded at the first appointment, followed by the monitoring of body weight and adverse effects during treatment. The mean age of the 32 patients was 63.78 years (\u00b1 10.50 years), with 90.6% of patients being female. Their mean weight and BMI were 94.31\u2005\u00b1\u200514.82\u2009kg and 36.49\u2005\u00b1\u20055.34\u2009kg\/m\u00b2, respectively. The body weight loss percentages were 5.96% at week 4, 10.06% at week 8, 13.85% at week 12, and 15.80% at week 24 (all <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.0001). At week 24, 100% of the patients lost more than 5% and 10% of their initial weight, respectively. Nausea was the most common adverse effect observed, with no reported instances of pancreatitis. This study corroborates the findings of previous research in this field. Evidence indicates that liraglutide is both efficacious and safe for treating obesity in the elderly population.<\/jats:p>","DOI":"10.1097\/md.0000000000042155","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T11:00:40Z","timestamp":1746529240000},"page":"e42155","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Is liraglutide safe and effective in the elderly obese patients?: A single center experience"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1160-9340","authenticated-orcid":false,"given":"Alihan","family":"Oral","sequence":"first","affiliation":[{"name":"Biruni University, Medical Faculty, Internal Medicine Department, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3261-6689","authenticated-orcid":false,"given":"Celalettin","family":"K\u00fc\u00e7\u00fck","sequence":"additional","affiliation":[{"name":"Biruni University, Vocational School, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2222-5521","authenticated-orcid":false,"given":"Yunus","family":"Kayalar","sequence":"additional","affiliation":[{"name":"Florence Nightingale Hospital, Internal Medicine Department, Istanbul, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250904","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1159\/000442721","article-title":"European Guidelines for Obesity Management in Adults.","volume":"8","author":"Yumuk","year":"2015","journal-title":"Obes Facts"},{"key":"R3-20250904","article-title":"WHO European Regional Obesity Report","year":"2022"},{"key":"R4-20250904","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0\u2009mg of liraglutide in weight management.","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"R5-20250904","doi-asserted-by":"crossref","first-page":"E875","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline.","volume":"192","author":"Wharton","year":"2020","journal-title":"CMAJ"},{"key":"R6-20250904","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes (Lond)"},{"key":"R7-20250904","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 Diabetes: the SCALE diabetes randomized clinical trial.","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"R8-20250904","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0\u2009mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obes (Lond)"},{"key":"R9-20250904","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.","volume":"38","author":"van Can","year":"2014","journal-title":"Int J Obes (Lond)"},{"key":"R10-20250904","first-page":"4","article-title":"Standards of care in diabetes-2023 abridged for primary care providers.","volume":"41","year":"2022","journal-title":"Clin Diabetes"},{"key":"R11-20250904","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO).","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"R12-20250904","article-title":"Guidelines for the management of obesity","year":"2019"},{"key":"R13-20250904","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1210\/clinem\/dgab359","article-title":"Approach to Obesity in the Older Population.","volume":"106","author":"Buch","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-20250904","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.ijo.0803005","article-title":"Health consequences of obesity in the elderly: a review of four unresolved questions.","volume":"29","author":"Zamboni","year":"2005","journal-title":"Int J Obes (Lond)"},{"key":"R15-20250904","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41574-018-0062-9","article-title":"Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies.","volume":"14","author":"Batsis","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"R16-20250904","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40520-015-0525-y","article-title":"Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study.","volume":"28","author":"Perna","year":"2016","journal-title":"Aging Clin Exp Res"},{"key":"R17-20250904","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41366-024-01529-z","article-title":"Obesity pharmacotherapy in older adults: a narrative review of evidence.","volume":"49","author":"Henney","year":"2024","journal-title":"Int J Obes (Lond)"},{"key":"R18-20250904","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/oby.22726","article-title":"Liraglutide 3.0\u2009mg and Intensive Behavioral Therapy (IBT) for obesity in primary care: the SCALE IBT Randomized Controlled Trial.","volume":"28","author":"Wadden","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"R19-20250904","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.3390\/biomedicines11102785","article-title":"Impact of Treatment with GLP1 receptor agonists, liraglutide 3.0\u2009mg and Semaglutide 1.0\u2009mg, While on a waiting list for bariatric surgery.","volume":"11","author":"Rubio-Herrera","year":"2023","journal-title":"Biomedicines"},{"key":"R20-20250904","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/bjs\/znae284","article-title":"Role of obesity-management medications before and after metabolic bariatric surgery: a systematic review.","volume":"111","author":"Cohen","year":"2024","journal-title":"Br J Surg"},{"key":"R21-20250904","doi-asserted-by":"crossref","first-page":"e2433326","DOI":"10.1001\/jamanetworkopen.2024.33326","article-title":"One-year weight reduction with semaglutide or liraglutide in clinical practice.","volume":"7","author":"Gasoyan","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R22-20250904","first-page":"561","article-title":"Semaglutide 2.4\u2009mg versus Liraglutide 3\u2009mg for the treatment of obesity in Greece: a short-term cost-effectiveness analysis.","volume":"25","author":"Papantoniou","year":"2025","journal-title":"PharmacoEcon Open"},{"key":"R23-20250904","doi-asserted-by":"crossref","first-page":"6121","DOI":"10.3390\/jcm13206121","article-title":"Real-world clinical effectiveness of liraglutide for weight management in T\u00fcrkiye: insights from the LIRA-TR Study.","volume":"13","author":"Oral","year":"2024","journal-title":"J Clin Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T12:01:06Z","timestamp":1756987266000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":22,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042155","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]}}}